<DOC>
	<DOC>NCT01745159</DOC>
	<brief_summary>To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (DE) in paediatric patients over a period of 6 months.</brief_summary>
	<brief_title>Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis</brief_title>
	<detailed_description>This study includes three periods. First a screening period of up to one week. Second an open-label treatment period of up to six weeks where all participants apply tacrolimus ointment. Third an open-label disease control period of up to six months where half of the participants apply tacrolimus ointment and the other half of the participants do not apply treatment.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1. Diagnosed as AD according to Williams diagnostic criteria. 2. Moderate or severe atopic dermatitis according to the criteria of Rajka and Langeland 3. At least approximately 10 % of body area 4. Patient is able to reach the centre within 3 days in case of a disease exacerbation. 5. Patient`s legal representative(s) has/have given written informed consent. If the patient is capable of understanding the purposes and risks of the trial, written informed consent has been obtained from the patient as well</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>Protopic</keyword>
	<keyword>pediatric</keyword>
	<keyword>atopic dermatitis</keyword>
	<keyword>China</keyword>
</DOC>